Qingdao Haier Biomedical Co Ltd (688139) — Capital Reinvestment Ratio

Latest as of June 2023: 7.36x

Qingdao Haier Biomedical Co Ltd (688139) has a Capital Reinvestment Ratio of 7.36x as of June 2023, meaning it reinvests 7% of its operating cash flow (CN¥7.33 Million) in capital expenditures (CN¥53.93 Million). Check how tangible is Qingdao Haier Biomedical Co Ltd's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

7.36x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥7.33 Million
CNY

Capital Expenditures

CN¥53.93 Million
CNY

Data as of

Jun 2023
Most recent filing

Qingdao Haier Biomedical Co Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Qingdao Haier Biomedical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Qingdao Haier Biomedical Co Ltd operating cash flow efficiency.

Annual Capital Reinvestment Ratio for Qingdao Haier Biomedical Co Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Qingdao Haier Biomedical Co Ltd from 2016 to 2025. See Qingdao Haier Biomedical Co Ltd (688139) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.45x CN¥267.89 Million CN¥119.25 Million ▲ +2.5%
2024 0.43x CN¥291.67 Million CN¥126.70 Million ▼ -38.9%
2023 0.71x CN¥249.26 Million CN¥177.18 Million ▲ +52.8%
2022 0.47x CN¥632.43 Million CN¥294.24 Million ▲ +43.8%
2021 0.32x CN¥632.43 Million CN¥204.69 Million ▲ +153.4%
2020 0.13x CN¥696.62 Million CN¥88.99 Million ▼ -78.7%
2019 0.60x CN¥280.49 Million CN¥168.40 Million ▲ +29.0%
2018 0.47x CN¥149.00 Million CN¥69.33 Million ▲ +155.8%
2017 0.18x CN¥148.32 Million CN¥26.98 Million ▲ +176.8%
2016 0.07x CN¥220.72 Million CN¥14.50 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow